

a9
cont. of the casing tube 6 include $\text{Sr}_2\text{P}_2\text{O}_7\cdot\text{Eu}$, $(\text{SrMg})_2\text{P}_2\text{O}_7\cdot\text{Eu}$, $\text{Sr}_5\text{Cl}(\text{PO}_4)_3\cdot\text{Eu}$, $\text{BaMg}_2\text{Al}_{18}\text{O}_{27}\cdot\text{Eu}$,
 $\text{SrMgAl}_{18}\text{O}_{50}\cdot\text{Eu}$, $\text{BaMg}_2\text{Al}_{16}\cdot\text{Eu}\cdot\text{Mn}$, $\text{Sr}_3(\text{PO}_4)_2\cdot\text{Eu}$, $\text{Ba}_3(\text{PO}_4)_2\cdot\text{Eu}$, $\text{CaWO}_4\cdot\text{Pb}$ and CaWO_4 .

In the Abstract:

Amend the abstract as follows:

a10
"THE SCOPE OF THE DISCLOSURE"
An irradiation device for therapeutic and cosmetic purposes including the treatment of primary T cell mediated skin disorders, in particular of atopic dermatitis (neurodermatitis), cutaneous T cell lymphoma, lichen ruber, alopecia areata, systemic lupus erythematoses and psoriasis and for cosmetic tanning, has at least one optical radiation source which, on an area to be irradiated, generates an irradiance in the wavelength range from 400 - 440 nm of at least 2 mW/cm² and generates an irradiance in the wavelength range from 300 - 400 nm of less than 21% of the irradiance in the wavelength range from 400 - 440 nm.

[(Fig. 2)]

In the Claims:

Please amend the amended version of claim 1 (as amended on August 4, 2000 in the international phase) and original claims 2-14 and add new claim 15 as follows:

a11
Sub B1
1. (Amended) An irradiation device for therapeutic applications for the treatment of primary T cell mediated skin disorders including atopic dermatitis (neurodermatitis), cutaneous T cell lymphoma, lichen ruber, alopecia areata, systemic lupus erythematoses and psoriasis and cosmetic applications including cosmetic tanning, wherein